Physician profile
Stephen N Zonca
NPI 1255394482
$1,679.45
in general payments reported to CMS, 2019-2025
13 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $238 · 2021: $63.71 · 2022: $330 · 2023: $184 · 2024: $156 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $481.75 | 2019-2023 | Xeomin |
| Mentor Worldwide LLC | $319.55 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer, Mentor Cpx 2 Breast Tissue Expander |
| Musculoskeletal Transplant Foundation INC. | $183.09 | 2020 | |
| Galderma Laboratories, L.P. | $156.29 | 2019 | |
| Checkpoint Surgical, INC | $103.90 | 2022 | |
| Kci USA, INC. | $93.03 | 2019 | |
| Stryker Corporation | $83.44 | 2020-2023 | Spy-Phi System |
| Smith+Nephew, INC. | $56.41 | 2019-2021 | |
| Abbvie INC. | $45.55 | 2023 | Natrelle Saline-Filled Breast Implants, Alloderm |
| Integra Lifesciences Corporation | $43.80 | 2024-2025 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Lemaitre Vascular, INC. | $41.50 | 2025 | Artegraft Vascular Graft |
| Acelrx Pharmaceuticals, INC. | $36.82 | 2021-2022 | |
| Allergan, INC. | $34.32 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Zonca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.